Home / TAK-279-PsO-3004
TAK-279-PsO-3004
Recruiting

A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

Clinicaltrials.gov
#NCT06973291
|
|

About this clinical trial

The main aim of this study is to assess whether zasocitinib works better than deucravacitinib in treating participants with moderate-to-severe plaque psoriasis. Participants will take one tablet daily of either zasocitinib or a matching placebo, along with one capsule daily of either over-encapsulated deucravacitinib or a matching placebo, for a duration of 16 weeks. Participants will be in the study for up to 25 weeks, which includes screening period of up to 35 days, a 16-week treatment period, and a 4-week safety follow-up period.

US
PL
CA
5+
Interventional Phase 3 clinical trial.

At a glance

What medical conditions are being studied?

Plaque Psoriasis

What is the clinical trial testing?

Zasocitinib, Deucravacitinib, Placebo to match zasocitinib, Placebo to match deucravacitinib

How many participants are being enrolled?

600

Are placebos part of the clinical trial?

Yes

When is the clinical trial being conducted?

Jul 2025 - Jul 2026

How long is participation in the clinical trial?

Participants will be in the study for about 25 weeks.

Key requirements

Sexes

All

Age

18+ Years

Healthy volunteers?

No

Entry criteria

Men and Women aged 18 years or older can participate.
Must have stable and long-term moderate-to-severe plaque psoriasis for at least 6 months before study start.
Must have a psoriasis area and severity index (PASI) score of 12 or more at study start.
Must have a static physician’s global assessment (sPGA) score of 3 or more at study start.
Must have 10% or more of their body (body surface area or BSA) covered by plaque psoriasis at study start.
Cannot have psoriasis without plaques.
Cannot have taken zasocitinib, deucravacitinib, or other similar medicines.
Cannot be treated for other conditions related to the immune system.
Cannot have a current infection or a history of certain types of infections.
Additional entry criteria will be discussed with the study doctor.

Locations

Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting
Will Be Recruiting